Alnylam Pharma (ALNY) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jefferies Cuts Price Target on Alnylam Pharma (ALNY) Following 1Q
May 3, 2016 9:40 AM EDTJefferies maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), and cut the price target to $119.00 (from $122.00), following the company's 1Q earnings report. ALNY reported 1Q16 revenues of $7.3M, ahead of consensus estimates of 7.8M. The company ended the quarter with... More
Leerink Cuts Alnylam (ALNY) PT to $107
May 3, 2016 8:14 AM EDTLeerink Partners analyst, Michael Schmidt, recapped the Alnylam Pharmaceuticals (NASDAQ: ALNY) pipeline update from 1Q results and cut his price target but maintained his Outperform rating. The PT drops to $107 from $120 but still offers 55% upside.
Pipeline updates: (1) Enrollment of the Revusiran Ph III trial in... More
